Jefferies analyst Akash Tewari downgraded Arvinas (ARVN) to Hold from Buy with a price target of $10, down from $52.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Oppenheimer surprised by ‘hasty’ decision to cull frontline Vepdeg development
- Arvinas reports Q1 EPS $1.14 vs (97c) last year
- Arvinas Showcases Promising Preclinical Data at AACR
- Arvinas reports data from preclinical combination studies of ARV-393
- Arvinas price target lowered to $21 from $65 at Truist